Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast CancerC. Domergue, Anne Patsouris, Jean‐Sébastien Frenel et al.|Cancers|2022Cited by 67
156P Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)C. Domergue, Anne Patsouris, E. Martin et al.|Annals of Oncology|2021Cited by 3